Skip to main content
. 2020 Apr 14;43(6):1352–1355. doi: 10.2337/dc19-1892

Figure 1.

Figure 1

Change from baseline in NASH-related biomarkers ALT (A), AST (B), K-18 (C), Pro-C3 (D), and adiponectin (E) through 26 weeks in patients with T2DM. Data are LSM (SE). Modified intention-to-treat population excludes data after study drug discontinuation or use of glucose-lowering rescue medication. *P < 0.05 change from baseline; #P < 0.05 vs. placebo; ‡P < 0.05 vs. dulaglutide.